Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study

被引：1

作者：

Zhang, P. ^{[1
]}

Gong, J. ^{[2
]}

Guo, H. ^{[3
]}

Han, W. ^{[4
]}

Cao, B. ^{[5
]}

Zhang, J. ^{[6
]}

Niu, Z. ^{[7
]}

Cheng, Y. ^{[8
]}

He, C. ^{[9
]}

Fan, J. ^{[10
]}

Peng, P. ^{[11
]}

Sun, C. ^{[12
]}

Wang, H. ^{[12
]}

Yu, Y. ^{[12
]}

Zhu, Y. ^{[12
]}

Wu, Y. ^{[12
]}

Li, Q. ^{[12
]}

Huang, P. ^{[12
]}

Wu, F. ^{[11
]}

Shen, L. ^{[13
]}

机构：

[1] Peking Univ, GI Dept, Beijing Canc Hosp, Canc Hosp, Beijing, Peoples R China

[2] Peking Univ Canc Hosp & Inst, Gastrointestinal Oncol, Beijing, Peoples R China

[3] Nanjing Univ, Affiliated Hosp, Nanjing Drum Tower Hosp, Sch Med,Urol, Nanjing, Peoples R China

[4] Hunan Canc Hosp, Urol, Changsha, Peoples R China

[5] Peking Univ Third Hosp, Dept Oncol, Beijing, Peoples R China

[6] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China

[7] Shandong Univ, Dept Gastroenterol, Shandong Canc Hosp, Jinan, Peoples R China

[8] Jilin Canc Hosp, Thorac Oncol Dept, Changchun, Jilin, Peoples R China

[9] Henan Canc Hosp, Urol, Zhengzhou, Peoples R China

[10] TransThera Sci US Inc, Clin Div, Gaithersburg, MD USA

[11] TransThera Sci Nanjing Inc, Nanjing, Peoples R China

[12] TransThera Sci Nanjing Inc, Clin Dept, Nanjing, Peoples R China

[13] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1856

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

670P

引用

页码：S471 / S471

页数：1

共 50 条

[1] Tinengotinib (TT-00420) in combination with atezolizumab in Chinese patients (pts) with biliary tract carcinoma (BTC): Preliminary efficacy and safety results from a phase Ib/II study.
Zhang, Panpan
Gong, Jifang
Niu, Zuoxing
Cheng, Ying
Fan, Jean
Peng, Peng
Sun, Caixia
Wang, Hui
Yu, Yingying
Zhu, Yujia
Wu, Yingtong
Li, Qing
Huang, Peng
Wu, Frank
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 473 - 473
[2] Tinengotinib (TT-00420) in combination with atezolizumab (atezo) in Chinese patients (pts) with biliary tract carcinoma (BTC): Efficacy and safety results from a phase Ib/II study
Zhang, P.
Gong, J.
Niu, Z.
Cheng, Y.
Cao, B.
Hou, X.
Fan, J.
Peng, P.
Sun, C. A.
Wang, H.
Yu, Y.
Zhu, Y.
Li, Q.
Huang, P.
Wu, F.
Shen, L.
ANNALS OF ONCOLOGY, 2024, 35 : S1460 - S1460
[3] Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial
Piha-Paul, Sarina A.
Goel, Sanjay
Liao, Chih-Yi
Gabrail, Nashat Y.
Dayyani, Farshid
Kazmi, Syed Mohammad Ali
Yuan, Yuan
Lavasani, Sayeh Moazami
Fan, Jean
Peng, Peng
Sun, Caixia
Wang, Hui
Hennessy, Katie
Fu, Ximei
Ni, Shumao
Tan, Hui Xian
Ngo, Brenda
Ru, Qinhua Cindy
Wu, Frank
Javle, Milind M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors
Piha-Paul, Sarina A.
Xu, Binghe
Dumbrava, Ecaterina E.
Fu, Siqing
Karp, Daniel D.
Meric-Bernstam, Funda
Hong, David S.
Rodon, Jordi A.
Tsimberidou, Apostolia M.
Raghav, Kanwal
Ajani, Jaffer A.
Conley, Anthony P.
Mott, Frank
Fan, Ying
Fan, Jean
Peng, Peng
Wang, Hui
Ni, Shumao
Sun, Caixia
Qiang, Xiaoyan
Levin, Wendy J.
Ngo, Brenda
Ru, Qinhua Cindy
Wu, Frank
Javle, Milind M.
ONCOLOGIST, 2024, 29 (04): : e514 - e525
[5] Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors.
Piha-Paul, Sarina Anne Anne
Xu, Binghe
Janku, Filip
Dumbrava, Ecaterina Elena
Fu, Siqing
Karp, Daniel D.
Meric-Bernstam, Funda
Hong, David S.
Ahnert, Jordi Rodon
Tsimberidou, Apostolia Maria
Javle, Milind M.
Fan, Ying
Peng, Peng
Levin, Wendy J.
Ngo, Brenda
Wang, Hui
Sun, Caixia
Ru, Qinhua Cindy
Wu, Frank
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] Phase I study of TT-00420, a multiple kinase inhibitor, in patients with triple negative breast cancers and other advanced solid tumors
Piha-Paul, Sarina A.
Ileana-Dumbrava, Ecaterina
Janku, Filip
Karp, Daniel D.
Meric-Bernstam, Funda
Rodon, Jordi
Ngo, Brenda
Peng, Peng
Wu, Frank
CANCER RESEARCH, 2020, 80 (16)
[7] First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors
Piha-Paul, Sarina Anne
Xu, Binghe
Raghav, Kanwal Pratap Singh
Meric-Bernstam, Funda
Janku, Filip
Dumbrava, Ecaterina Elena
Fu, Siqing
Karp, Daniel D.
Ahnert, Jordi Rodon
Conley, Anthony Paul
Mott, Frank
Ajani, Jaffer A.
Hong, David S.
Fan, Ying
Peng, Peng
Levin, Wendy J.
Ngo, Brenda
Ru, Qinhua Cindy
Wu, Frank
Javle, Milind M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors
Carneiro, Benedito A.
Jotte, Robert M.
Gabrail, Nashat Y.
Wentzel, Kristopher
Huang, Funan
Chaturvedi, Shalini
Weispfenning, Anke
Hiemeyer, Florian
Morcos, Peter N.
Soler, Lidia Mongay
Childs, Barrett H.
Hansen, Aaron R.
CANCER RESEARCH COMMUNICATIONS, 2025, 5 (03): : 444 - 457
[9] Safety and efficacy of copanlisib in combination with nivolumab: A phase Ib study in patients with advanced solid tumors
Carneiro, Benedito A.
Jotte, Robert
Gabrail, Nashat
Hamid, Omid
Huang, Funan
Chaturvedi, Shalini
Herpers, Matthias
Soler, Lidia Mongay
Childs, Barrett H.
Hansen, Aaron
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[10] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
Piha-Paul, Sarina Anne
Wan, Qunfang
Xiong, Wendy
Peng, Peng
Yang, Xiaoju
Wu, Henry
Ngo, Brenda
Wu, Frank
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →